| HOME >> BIOLOGY >> TECHNOLOGY |
MX-4509 0.0 0.0 0.2 0.2
Other Projects 0.0 0.0 0.3 0.3
---------------------------------
Total Program Expenses 0.4 0.4 3.1 3.2
---------------------------------
Unattributed Expenses
Personnel 0.7 0.6 2.7 2.7
Patent costs 0.3 0.2 0.8 0.9
Other 0.3 0.1 0.9 0.9
---------------------------------
Total Unattributed Expenses 1.3 0.9 4.4 4.5
---------------------------------
Total Research & Development Expenses $1.7 $1.3 $7.5 $7.7
---------------------------------
---------------------------------
(1) Before amortization expense, technology and license acquisition
costs, and write-offs of intangibles assets.
(2) Value of $0.0 million represents $nil to ~$50,000 in expenses during
the period.
Our Omiganan programs are being advanced by development and commercialization partners (Cadence Pharmaceuticals and Cutanea Life Sciences).
Celgosivir program costs were $0.4 million in Q1/08, relatively unchanged from Q1/07.
Costs in the MX-2401 program in Q1/08 were nominal (less than $0.1 million) (Q1/07: nominal). The Q1/08 MX-2401 program costs are net of $0.06 million in TPC assistance (Q1/07: $0.02 million).
Research and development costs not allocated to programs were $1.3
million in Q1/08 compared to $0.9 million in Q1/07. The approximate
'/>"/>
| SOURCE MIGENIX Inc. Copyright©2007 PR Newswire. All rights reserved |